Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | BRAF | P15056 | 6/20 | 0.53 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7587620 | 0.89 | EGFR (0.59) | EGFRERBB2BRAFCSNK2A1KDR | |
| SCHEMBL7575756 | 0.89 | EGFR (0.55) | EGFRERBB2HPGDHTTBRAF | |
| SCHEMBL7587577 | 0.87 | EGFR (0.57) | EGFRERBB2HPGDHTTBRAF | |
| SCHEMBL8315593 | 0.86 | EGFR (0.59) | EGFRERBB2HPGDHTTBRAF | |
| SCHEMBL7578794 | 0.85 | EGFR (0.66) | EGFRBRAF | |
| SCHEMBL6997201 | 0.85 | EGFR (0.71) | EGFRERBB2HPGDHTTBRAF | |
| SCHEMBL7581140 | 0.85 | EGFR (0.73) | EGFRERBB2BRAF | |
| SCHEMBL7585168 | 0.85 | EGFR (0.73) | EGFRERBB2HPGDHTTBRAF | |
| SCHEMBL7574992 | 0.84 | EGFR (0.60) | EGFRERBB2HPGDHTTBRAF | |
| SCHEMBL6991323 | 0.84 | EGFR (0.61) | EGFRERBB2HPGDHTTBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020082420-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082420-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | PKD1, REN, CYP11B1 | EGFR 1041/4885ERBB2 2419/4885HPGD 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.